遅発性ポンペ病患者の血中の抗体レベルとバイオマーカーに関する研究
遅発性ポンペ病患者における AAV8 に対する抗体の血清保有率とバイオマーカーの評価を評価する研究
Pompe disease is a genetic condition which causes muscle weakness over time. People with Pompe disease have a faulty gene that makes an enzyme called acid alpha-glucosidase (or GAA). This enzyme breaks down a type of sugar called glycogen. Without this enzyme, there is a build-up of glycogen in the cells of the body. This causes muscle weakness and other symptoms. Pompe disease can happen at any age, but in late-onset Pompe disease, symptoms generally start from 12 months old onwards.
The standard treatment for people with Pompe disease is to receive regular infusions of the GAA enzyme. This is known as enzyme replacement therapy. However, people can build up antibodies against the GAA enzyme over time.
Gene therapy is used to treat conditions caused by a faulty gene. It works by replacing the faulty gene with a working gene inside the cells of the body. The working gene is delivered into the cells using certain viruses as carriers (vectors). Viruses are often used as carriers as they can easily get inside cells. The genetic material of the original virus is replaced with the working gene, so only the working gene gets inside the cells. A common virus used as a carrier in gene therapy is the adeno-associated virus (or AAV). This is like an adenovirus, which causes the common cold.
The original type of AAV does not cause any harm to humans. However, people that have previously been infected with the original type of AAV may have built up antibodies against AAV. These antibodies may stop the AAV carrier with the working gene getting inside the cells.
Researchers want to learn more about antibody levels against AAV and the GAA enzyme in people with late-onset Pompe disease. They also want to learn about other substances in the blood that provide more information about late-onset Pompe disease. These are known as biomarkers.
In this study, older teenagers and adults with late-onset Pompe disease will take part. They will not have had gene therapy using AAV. There will be 2 groups - those who have never had enzyme replacement therapy, and those who have had enzyme replacement therapy for 6 months or more. No study treatment will be given during the study, but blood and urine samples will be taken for testing.
The main aims of the study are to check antibody levels against AAV8 (a type of AAV) in people with late-onset Pompe disease who had not received any treatment using AAV, to check antibody levels against the GAA enzyme in people previously treated with GAA as part of enzyme replacement therapy, to check levels of biomarkers for Pompe disease, and to check for medical problems.
In the study, people will visit the study clinic several times. Some visits may be in the person's home. The first visit is to check if they can take part. Those who can take part will have a medical examination, and have their vital signs checked. Vital signs include blood pressure, heart rate, breathing rate and temperature. Blood samples will be taken to check antibody levels against the GAA enzyme and against AAV8. Blood and urine samples will also be taken to check for biomarkers for Pompe disease. Blood and urine samples will be taken about every 4 months for up to 2 years.
調査の概要
詳細な説明
No investigational drug will be administered to participants in this study. Blood and urine will be collected as part of the study. The duration of the study is approximately 2 years, participants may withdraw at any time.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- Emory Clinic
-
-
Kansas
-
Kansas City、Kansas、アメリカ、66160
- University of Kansas Medical Center
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- University of Michigan
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55404
- Children's Hospitals and Clinics of Minnesota
-
-
New Jersey
-
Hackensack、New Jersey、アメリカ、07601
- Hackensack University Medical Center
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45221
- University of Cincinnati
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- University of Pennsylvania
-
Pittsburgh、Pennsylvania、アメリカ、15213
- University of Pittsburgh Medical Center
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84132
- University of UTAH - PPDS
-
-
Virginia
-
Fairfax、Virginia、アメリカ、22030
- Lysosomal and Rare Diseases Research and Treatment Center, Inc.
-
-
-
-
-
Cambridge、イギリス
- UK44003
-
Newcastle upon Tyne、イギリス
- UK44001
-
Salford、イギリス
- UK44004
-
-
-
-
-
Florence、イタリア
- IT39002
-
Gussago、イタリア
- IT39005
-
Messina、イタリア
- IT39012
-
Milan、イタリア
- IT39009
-
Milan、イタリア
- IT39011
-
Pavia、イタリア
- IT39008
-
Pisa、イタリア
- IT39006
-
Roma、イタリア
- IT39004
-
Udine、イタリア
- IT39003
-
-
-
-
-
Adelaide、オーストラリア
- AU61003
-
Herston、オーストラリア
- AU61001
-
-
-
-
-
Edmonton、カナダ
- CN15003
-
Montreal、カナダ
- CA15001
-
-
-
-
-
Albacete、スペイン
- ES34003
-
Barcelona、スペイン
- ES34004
-
Donostia / San Sebastian、スペイン
- ES34009
-
L'Hospitalet de Llobregat、スペイン
- ES34007
-
Madrid、スペイン
- ES34001
-
Madrid、スペイン
- ES34005
-
Valencia、スペイン
- ES34002
-
-
-
-
-
Bonn、ドイツ
- DT49005
-
Essen、ドイツ
- DT49004
-
Höchheim、ドイツ
- DT49003
-
Münster、ドイツ
- DT49006
-
-
-
-
-
Angers、フランス
- FR33006
-
Garches、フランス
- FR33009
-
Lille、フランス
- FR33005
-
Limoges、フランス
- FR33007
-
Marseille、フランス
- FR33002
-
Nantes、フランス
- FR33003
-
Nice、フランス
- FR33004
-
Strasbourg、フランス
- FR33001
-
-
-
-
-
Flamengo、ブラジル
- BR55003
-
Porto Alegre、ブラジル
- BR55002
-
São Paulo、ブラジル
- BR55001
-
-
-
-
-
Taipei、台湾
- TW88601
-
Taipei、台湾
- TW88602
-
Taoyuan City、台湾
- TW88603
-
-
-
-
-
Kodaira-Shi、日本
- National Center of Neurology and Psychiatry
-
Shinjuku-Ku、日本
- Tokyo Women's Medical University Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Participant has a documented clinical diagnosis of LOPD.
- Participant is enzyme replacement therapy ERT-naïve (ERT-N) or if the participant is currently taking an approved ERT treatment or is participating in an ERT-interventional study, the ERT must have been received for at least 6 months or more (ERT-experienced [ERT-E]).
- Participant is willing and able to comply with study visits and procedures.
- Participant agrees to not start participating in any other clinical study involving an investigational study treatment, including ERT, while participating in this study.
Exclusion Criteria:
- Participant previously received an AAV-related product (any serotype).
- Participant is currently participating in a Pompe-related interventional study (other than ERT-interventional studies) or has received gene or cell therapy.
- Participant requires any invasive or noninvasive ventilation support while awake and upright (non-invasive support while sleeping with either continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) is acceptable for eligibility).
- Participant is unable to ambulate (assistive devices [e.g., cane or walker] are acceptable for eligibility).
- Participants who have received any ERT for less than 6 months as of the Baseline visit are not eligible.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
他の:Participants with Late-Onset Pompe Disease
Adolescent or adult participants with LOPD. |
No investigational drug will be administered to participants in this study. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Occurrence of total antibodies to AAV8
時間枠:Up to 2 years
|
Antibodies to AAV8 will be recorded from serum blood samples collected. |
Up to 2 years
|
|
Occurrence of neutralizing antibodies to AAV8
時間枠:Up to 2 years
|
Antibodies to AAV8 will be recorded from serum blood samples collected. |
Up to 2 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Seroconversion of antibodies to AAV8 over time
時間枠:Up to 2 years
|
Seroconversion of antibodies to AAV8 will be recorded from serum blood samples collected. |
Up to 2 years
|
|
Creatine kinase [CK] levels
時間枠:Up to 2 years
|
CK levels will be recorded from blood plasma samples collected. |
Up to 2 years
|
|
Urine glucose tetrasaccharide [Glc4]/hexose tetrasaccharide [Hex4] over time
時間枠:Up to 2 years
|
Glc4/Hex4 will be recorded from urine samples collected. |
Up to 2 years
|
|
Occurrence of anti-GAA antibodies in participants on ERT
時間枠:Up to 2 years
|
Anti-GAA antibodies will be recorded from serum blood samples collected. |
Up to 2 years
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Medical Director、Astellas Gene Therapies
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- AT845-02
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。